CN1778325A - Disperse tablet for activating bood and stopping pain and its preparation - Google Patents
Disperse tablet for activating bood and stopping pain and its preparation Download PDFInfo
- Publication number
- CN1778325A CN1778325A CNA2004100908978A CN200410090897A CN1778325A CN 1778325 A CN1778325 A CN 1778325A CN A2004100908978 A CNA2004100908978 A CN A2004100908978A CN 200410090897 A CN200410090897 A CN 200410090897A CN 1778325 A CN1778325 A CN 1778325A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- total weight
- accounts
- tablet
- tablet total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine in the form of dispersing tablet for activating blood to relieve pain is prepared from 6 Chinese-medicinal materials including Chinese angelica root, notoginseng, borneol, ground bettle, etc. Its advantages are high disintegrating speed and high biologic utilization rate.
Description
Technical field
The present invention relates to Chinese medicine preparation, specifically is the dispersible tablet formulation of forming with Radix Angelicae Sinensis, Radix Notoginseng, Olibanum, Borneolum Syntheticum, Eupolyphaga Seu Steleophaga and Pyritum Six-element Chinese medicine, simultaneously, the invention still further relates to the preparation method of said preparation.
Background technology
At present, gone on the market the promoting blood circulation and stopping pain oral formulations two kinds of huoxue zhitong powder, huoxue zhitong san (Chinese Pharmacopoeia 2000 editions) and HUOXUE ZHIRONG JIAONANG (the 12 in Chinese traditional patent formulation preparation) are arranged.The instructions of taking of huoxue zhitong powder, huoxue zhitong san is with warm yellow wine or warm water delivery service, but direct the pulverizing makes because this dosage form is a medical material, meets liquid medicated powder and is gathered into agglomerate, takes inconvenience, and taste is bad, and influences the stripping and the absorption of active component.HUOXUE ZHIRONG JIAONANG is that medicinal powder is directly incapsulated shell, though solved the bad problem of taste, but the stripping of active component is slower, it is also just slower to absorb onset, and use the crude drug direct packaging, because the flowability of powder is poor, can cause bigger weight differential in the process of capsule subpackage.Chinese patent CN1438009, CN1513499, CN1544053 all adopt extraction step to prepare preparation, but the destroyed or loss of a part of effective ingredient meeting in leaching process reduces drug effect.
Summary of the invention
The purpose of this invention is to provide a kind of crude drug powder without extracting the promoting blood circulation and stopping pain dispersible tablet of directly making, solved loose, the problem of preparation that capsule and other extracting method are made, have following characteristics: 1, disintegration time weak point, good dispersing state, avoided former medicated powder in powder and the capsule to meet liquid being gathered into agglomerate, the active component stripping is rapider; 2, absorb fast, bioavailability is high, 3, features good taste, taking convenience can be swallowed, chew to contain and suck or with taking after the aqueous dispersion.4,, keep original drug effect of medical material without extraction.
The prescription of principal agent of the present invention and Chinese Pharmacopoeia 2000 editions are consistent to be:
Radix Angelicae Sinensis 400g Radix Notoginseng 80g Olibanum (system) 80g
Borneolum Syntheticum 20g Eupolyphaga Seu Steleophaga 200g Pyritum (forging) 120g
Prescription of the present invention can carry out suitable increase and decrease on the basis of above-mentioned pharmacopeia prescription.
The present invention is made up of above-mentioned crude drug powder and disintegrating agent, filler, binding agent, lubricant, correctives etc.Preparation method is a wet granule compression tablet.
Crude drug powder of the present invention accounts for 25%～90% of tablet total weight amount, and is preferred 35%～70%, and the method that crude drug is pulverized can be with reference to the method for making of Chinese Pharmacopoeia huoxue zhitong powder, huoxue zhitong san, for: all the other ground spices except that Borneolum Syntheticum are broken into fine powder, with the Borneolum Syntheticum porphyrize, with above-mentioned powder facing-up, sieve mixing.
Described disintegrating agent is selected from low-substituted hydroxypropyl cellulose, carboxymethylstach sodium, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone.The content of disintegrating agent accounts for 3%～25% of tablet total weight amount, and is preferred 5%～20%, and the adding mode of disintegrating agent both can adopt the mode that adds+add in also can adopting that adds.
Described filler is a microcrystalline Cellulose, and the content of filler accounts for 7%～50% of tablet total weight amount, preferred 25%～45%.
Described binding agent is selected from the water or the alcoholic solution of hypromellose, polyvidone, starch slurry etc., conventional concentration and method that used concentration and compound method can adopt the pharmaceutics teaching material to be instructed.
Described lubricant is selected from magnesium stearate, micropowder silica gel, Pulvis Talci etc.
Described correctives is selected from stevioside, aspartame, essence, maltose alcohol, saccharin sodium, protein sugar, sucrose, Mentholum, Mel etc., and consumption is a conventional amount used.
Described wet granule compression tablet method is that the supplementary material mixing is sieved, with binder solution system soft material, granulates, and oven dry, granulate adds adjuvant tablettings such as disintegrating agent, lubricant.
The specific embodiment
Following examples are in order to illustrate further the present invention, rather than scope of the present invention is provided constraints.
Embodiment 1
Radix Angelicae Sinensis 400g
Radix Notoginseng 80g
Olibanum (system) 80g
Borneolum Syntheticum 20g
Eupolyphaga Seu Steleophaga 200g
Pyritum (forging) 120g
Microcrystalline Cellulose 100g
Carboxymethyl starch sodium 200g
2% hypromellose is an amount of
Aspartame 2g
Fructus Citri Limoniae essence 2g
Magnesium stearate 10g
Make 1200 altogether
Method for making:
1, the ground spice of all the other except that Borneolum Syntheticum is broken into fine powder, with the Borneolum Syntheticum porphyrize, with above-mentioned powder facing-up, crosses 100 mesh sieves, mixing.
2, getting hypromellose adds water and makes 2% solution.
3, half carboxymethyl starch sodium of crude drug powder, microcrystalline Cellulose and recipe quantity is crossed 100 mesh sieve mix homogeneously, with 2% hypromellose system soft material.Granulate with 20 mesh sieves, dried 20 mesh sieve granulate 20 minutes for 50 ℃.The carboxymethyl starch sodium mix homogeneously that adds aspartame, Fructus Citri Limoniae essence, magnesium stearate, surplus, tabletting.
Embodiment 2
Radix Angelicae Sinensis 400g
Radix Notoginseng 80g
Olibanum (system) 80g
Borneolum Syntheticum 20g
Eupolyphaga Seu Steleophaga 200g
Pyritum (forging) 120g
Microcrystalline Cellulose 900g
Polyvinylpolypyrrolidone 100g
5% polyvidone is an amount of
Aspartame 4g
Fructus Citri Limoniae essence 4g
Magnesium stearate 20g
Make 2400 altogether
Method for making:
1, the ground spice of all the other except that Borneolum Syntheticum is broken into fine powder, with the Borneolum Syntheticum porphyrize, with above-mentioned powder facing-up, crosses 100 mesh sieves, mixing.
2, getting polyvidone adds water and makes 5% solution.
3, crude drug powder, microcrystalline Cellulose, polyvinylpolypyrrolidone are crossed 100 mesh sieves, and mix homogeneously is with 5% polyvidone system soft material.Granulate with 20 mesh sieves, dried 20 mesh sieve granulate 20 minutes for 50 ℃.Add aspartame, Fructus Citri Limoniae essence, magnesium stearate, mix homogeneously, tabletting.
Embodiment 3
Radix Angelicae Sinensis 400g
Radix Notoginseng 80g
Olibanum (system) 80g
Borneolum Syntheticum 20g
Eupolyphaga Seu Steleophaga 200g
Pyritum (forging) 120g
Microcrystalline Cellulose 400g
Cross-linking sodium carboxymethyl cellulose 60g
2% hypromellose is an amount of
Aspartame 3g
Fructus Citri Limoniae essence 3g
Magnesium stearate 15g
Make 2400 altogether
Method for making: 1, the ground spice of all the other except that Borneolum Syntheticum is broken into fine powder, with the Borneolum Syntheticum porphyrize, with above-mentioned powder facing-up, crosses 100 mesh sieves, mixing.
2, getting hypromellose adds water and makes 2% solution.
3, crude drug powder, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose are crossed 100 mesh sieves, and mix homogeneously is with 2% hypromellose system soft material.Granulate with 20 mesh sieves, dried 20 mesh sieve granulate 20 minutes for 50 ℃.Add aspartame, Fructus Citri Limoniae essence, magnesium stearate mix homogeneously, tabletting.
Embodiment 4
Radix Angelicae Sinensis 400g
Radix Notoginseng 80g
Olibanum (system) 80g
Borneolum Syntheticum 20g
Eupolyphaga Seu Steleophaga 200g
Pyritum (forging) 120g
Microcrystalline Cellulose 500g
Low-substituted hydroxypropyl cellulose 150g
2% hypromellose is an amount of
Aspartame 3g
Fructus Citri Limoniae essence 3g
Magnesium stearate 15g
Make 2400 altogether
Method for making:
1, the ground spice of all the other except that Borneolum Syntheticum is broken into fine powder, with the Borneolum Syntheticum porphyrize, with above-mentioned powder facing-up, crosses 100 mesh sieves, mixing.
2, getting hypromellose adds water and makes 2% solution.
3, crude drug powder, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose are crossed 100 mesh sieves, and mix homogeneously is with 2% hypromellose system soft material.Granulate with 20 mesh sieves, dried 20 mesh sieve granulate 20 minutes for 50 ℃.Add aspartame, Fructus Citri Limoniae essence, magnesium stearate mix homogeneously, tabletting.
Embodiment 5
Radix Angelicae Sinensis 400g
Radix Notoginseng 80g
Olibanum (system) 80g
Borneolum Syntheticum 20g
Eupolyphaga Seu Steleophaga 200g
Pyritum (forging) 60g
Microcrystalline Cellulose 350g
Carboxymethyl starch sodium 80g
2% hypromellose is an amount of
Aspartame 3g
Fructus Citri Limoniae essence 3g
Magnesium stearate 15g
Make 2400 altogether
Method for making:
1, the ground spice of all the other except that Borneolum Syntheticum is broken into fine powder, with the Borneolum Syntheticum porphyrize, with above-mentioned powder facing-up, crosses 100 mesh sieves, mixing.
2, getting hypromellose adds water and makes 2% solution.
3, crude drug powder, microcrystalline Cellulose, carboxymethyl starch sodium are crossed 100 mesh sieves, and mix homogeneously is with 2% hypromellose system soft material.Granulate with 20 mesh sieves, dried 20 mesh sieve granulate 20 minutes for 50 ℃.Add aspartame, Fructus Citri Limoniae essence, magnesium stearate mix homogeneously, tabletting.
Embodiment 6 dispersing uniformities
Assay method: get 2 of dispersible tablets, put jolting in the 100ml water, in 20 ℃ ± 1 ℃ water, 3 minutes all disintegrate and by No. 2 the sieve.
Sample determination dispersing uniformity with among above-mentioned 5 embodiment the results are shown in Table.
| Sample number | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Jitter time (s) | 130 | 81 | 120 | 56 | 135 |
The result as seen, the sample among 5 embodiment all meets the requirement of the dispersing uniformity of the relevant dispersible tablet of Chinese Pharmacopoeia.
Claims (10)
1, a kind of promoting blood circulation and stopping pain dispersible tablet is characterized in that containing the crude drug powder of Radix Angelicae Sinensis, Radix Notoginseng, Olibanum (system), Borneolum Syntheticum, Eupolyphaga Seu Steleophaga, Pyritum (forging) and disintegrating agent, filler.
2, pharmaceutical composition as claimed in claim 1, wherein the crude drug powder accounts for 25%～90% of tablet total weight.
3, pharmaceutical composition as claimed in claim 1, wherein the crude drug powder accounts for 35%～70% of tablet total weight.
4, pharmaceutical composition as claimed in claim 1, wherein disintegrating agent is selected from low-substituted hydroxypropyl cellulose, carboxymethylstach sodium, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone.
5, pharmaceutical composition as claimed in claim 1, wherein the consumption of disintegrating agent accounts for 3%～25% of tablet total weight amount.
6, pharmaceutical composition as claimed in claim 1, wherein the consumption of disintegrating agent accounts for 5%～20% of tablet total weight amount.
7, pharmaceutical composition as claimed in claim 1, wherein filler is a microcrystalline Cellulose.
8, pharmaceutical composition as claimed in claim 1, wherein the consumption of filler accounts for 7%～50% of tablet total weight amount.
9, pharmaceutical composition as claimed in claim 1, wherein the consumption of filler accounts for 25%～45% of tablet total weight amount.
10, pharmaceutical composition as claimed in claim 1 also contains binding agent, lubricant, correctives etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100908978A CN1778325A (en) | 2004-11-17 | 2004-11-17 | Disperse tablet for activating bood and stopping pain and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100908978A CN1778325A (en) | 2004-11-17 | 2004-11-17 | Disperse tablet for activating bood and stopping pain and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1778325A true CN1778325A (en) | 2006-05-31 |
Family
ID=36768862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100908978A Pending CN1778325A (en) | 2004-11-17 | 2004-11-17 | Disperse tablet for activating bood and stopping pain and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1778325A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319281A (en) * | 2011-09-30 | 2012-01-18 | 珠海安生凤凰制药有限公司 | Traditional Chinese medicine preparation for invigorating blood circulation and relieving pain and preparation method thereof |
| CN109106743A (en) * | 2018-09-28 | 2019-01-01 | 珠海安生凤凰制药有限公司 | A kind of blood-activating and pain-stopping capsules and preparation method thereof |
| CN112715944A (en) * | 2020-12-29 | 2021-04-30 | 江苏艾兰得营养品有限公司 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
-
2004
- 2004-11-17 CN CNA2004100908978A patent/CN1778325A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319281A (en) * | 2011-09-30 | 2012-01-18 | 珠海安生凤凰制药有限公司 | Traditional Chinese medicine preparation for invigorating blood circulation and relieving pain and preparation method thereof |
| CN102319281B (en) * | 2011-09-30 | 2012-09-26 | 珠海安生凤凰制药有限公司 | Traditional Chinese medicine preparation for invigorating blood circulation and relieving pain and preparation method thereof |
| CN109106743A (en) * | 2018-09-28 | 2019-01-01 | 珠海安生凤凰制药有限公司 | A kind of blood-activating and pain-stopping capsules and preparation method thereof |
| CN112715944A (en) * | 2020-12-29 | 2021-04-30 | 江苏艾兰得营养品有限公司 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1736471A (en) | Ginger preparation and preparation process thereof | |
| CN1872217A (en) | A medication for treating headache, and preparation method | |
| CN1850161A (en) | Medicine composition for treating pain and preparing method therefor | |
| CN1302772C (en) | Orally disintegrated sodium ferulate tablet and its prepn process | |
| CN1883480A (en) | A pharmaceutical composition containing rupatatine | |
| CN1608621A (en) | Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn | |
| CN1778325A (en) | Disperse tablet for activating bood and stopping pain and its preparation | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN101028329A (en) | Production and use for phyllanthin dispersing tablet preparation | |
| CN1698663A (en) | Ring form effervescence dosage and preparation method thereof | |
| CN1695624A (en) | Combination of medication of containing kurarinone and glycyrrhetic acid, and application | |
| CN1615844A (en) | Development of micro particle silybum marianum preparation | |
| CN1810278A (en) | Enteric coated Chinese medicine composition for treating cervical and lumbar spondylopathy | |
| CN1626143A (en) | Medication for treating pharyngitis | |
| CN1857482A (en) | Compound Chinese medicine preparation for clearing away heat, drying damp, disinsecting and stopping itch and its preparing process | |
| CN1660140A (en) | Activity combination of marine life and application | |
| CN101028318A (en) | Sustained andrographis paniculata preparation and its preparing method | |
| CN1698668A (en) | Motherwort extract dispersed tablet and preparation method of motherwort extract | |
| CN1562210A (en) | Burnet disintegration tablet of mouth and preparation method | |
| CN1814113A (en) | Medicine composition for treating hyperplasia of mammary glands and preparing technology | |
| CN101066252A (en) | Aminoglucose calcium tablet and its prepn process | |
| CN1634014A (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1714808A (en) | Method for preparing blood flow cutting off dispersing tablet | |
| CN1927372A (en) | Antiviral dispersant tablet and method for making same | |
| CN1788738A (en) | Medicinal preparation containing volatile oil and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20060531 |